GHP Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.05M | Hold |
60,364
| – | – | 0.08% | 240 |
|
|
2026
Q1 | $1.82M | Buy |
60,364
+9,480
| +19% | +$305K | 0.07% | 238 |
|
|
2025
Q4 | $1.59M | Hold |
50,884
| – | – | 0.07% | 246 |
|
|
2025
Q3 | $1.03M | Hold |
50,884
| – | – | 0.04% | 274 |
|
|
2025
Q2 | $853K | Hold |
50,884
| – | – | 0.04% | 278 |
|
|
2025
Q1 | $782K | Buy |
50,884
+18,819
| +59% | +$336K | 0.04% | 277 |
|
|
2024
Q4 | $707K | Hold |
32,065
| – | – | 0.03% | 283 |
|
|
2024
Q3 | $578K | Buy |
32,065
+30,265
| +1,681% | +$530K | 0.03% | 293 |
|
|
2024
Q2 | $29.3K | Hold |
1,800
| – | – | ﹤0.01% | 548 |
|
|
2024
Q1 | $25.4K | Sell |
1,800
-200
| -10% | -$2.52K | ﹤0.01% | 556 |
|
|
2023
Q4 | $20.9K | Hold |
2,000
| – | – | ﹤0.01% | 566 |
|
|
2023
Q3 | $17.3K | Hold |
2,000
| – | – | ﹤0.01% | 618 |
|
|
2023
Q2 | $19.6K | Sell |
2,000
-400
| -17% | -$3.24K | ﹤0.01% | 589 |
|
|
2023
Q1 | $21.2K | Hold |
2,400
| – | – | ﹤0.01% | 578 |
|
|
2022
Q4 | $21.9K | Hold |
2,400
| – | – | ﹤0.01% | 571 |
|
|
2022
Q3 | $19K | Hold |
2,400
| – | – | ﹤0.01% | 585 |
|
|
2022
Q2 | $18K | Hold |
2,400
| – | – | ﹤0.01% | 591 |
|
|
2022
Q1 | $23K | Buy |
+2,400
| New | +$20K | ﹤0.01% | 591 |
|
|
2019
Q2 | – | Sell |
-26,023
| Closed | -$408K | – | 310 |
|
|
2019
Q1 | $408K | Buy |
26,023
+4,300
| +20% | +$75.8K | 0.05% | 238 |
|
|
2018
Q4 | $335K | Sell |
21,723
-200
| -0.9% | -$4.1K | 0.05% | 247 |
|
|
2018
Q3 | $472K | Buy |
21,923
+620
| +3% | +$14.4K | 0.06% | 228 |
|
|
2018
Q2 | $518K | Hold |
21,303
| – | – | 0.07% | 225 |
|
|
2018
Q1 | $364K | Hold |
21,303
| – | – | 0.05% | 245 |
|
|
2017
Q4 | $404K | Buy |
21,303
+7,750
| +57% | +$117K | 0.06% | 242 |
|
|
2017
Q3 | $239K | Buy |
13,553
+200
| +1% | +$4.5K | 0.04% | 273 |
|
|
2017
Q2 | $444K | Buy |
13,353
+3,030
| +29% | +$93.8K | 0.07% | 236 |
|
|
2017
Q1 | $331K | Hold |
10,323
| – | – | 0.06% | 256 |
|
|
2016
Q4 | $374K | Hold |
10,323
| – | – | 0.07% | 239 |
|
|
2016
Q3 | $475K | Buy |
10,323
+500
| +5% | +$26.1K | 0.1% | 212 |
|
|
2016
Q2 | $493K | Hold |
9,823
| – | – | 0.11% | 205 |
|
|
2016
Q1 | $526K | Sell |
9,823
-400
| -4% | -$23.5K | 0.12% | 197 |
|
|
2015
Q4 | $671K | Sell |
10,223
-152
| -1% | -$9.39K | 0.16% | 157 |
|
|
2015
Q3 | $586K | Hold |
10,375
| – | – | 0.15% | 163 |
|
|
2015
Q2 | $642K | Hold |
10,375
| – | – | 0.16% | 156 |
|
|
2015
Q1 | $646K | Buy |
10,375
+170
| +2% | +$9.88K | 0.17% | 153 |
|
|
2014
Q4 | $587K | Sell |
10,205
-150
| -1% | -$8.36K | 0.16% | 152 |
|
|
2014
Q3 | $557K | Buy |
10,355
+60
| +0.6% | +$3.18K | 0.16% | 151 |
|
|
2014
Q2 | $540K | Hold |
10,295
| – | – | 0.16% | 153 |
|
|
2014
Q1 | $544K | Buy |
10,295
+240
| +2% | +$11.1K | 0.17% | 144 |
|
|
2013
Q4 | $403K | Sell |
10,055
-400
| -4% | -$15.8K | 0.13% | 174 |
|
|
2013
Q3 | $395K | Hold |
10,455
| – | – | 0.14% | 169 |
|
|
2013
Q2 | $410K | Buy |
+10,455
| New | +$407K | 0.16% | 156 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
GHP Investment Advisors's TEVA Position: Q2 2026 in Review
GHP Investment Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 60,364 shares worth $2.05M. The position accounts for 0.08% of the portfolio, ranked #240.
GHP Investment Advisors first reported a position in TEVA in Q2 2013 and has held it in 42 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- GHP Investment Advisors held 60,364 shares of Teva Pharmaceuticals worth $2.05M as of Q2 2026.
- GHP Investment Advisors left its Teva Pharmaceuticals share count unchanged in Q2 2026.
- Teva Pharmaceuticals made up 0.08% of GHP Investment Advisors's portfolio in Q2 2026, its #240 holding.
- GHP Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.